程序性死亡受体1抑制剂治疗甲状腺癌的研究进展  

Research progress of programmed cell death-1 inhibitors in the treatment of thyroid carcinoma

作　　者：王艺霏 薛海波[1] Wang Yifei;Xue Haibo(Department of Endocinology,Binzhou Medical University Hospital,Binzhou 256603,China)

机构地区：[1]滨州医学院附属医院内分泌科,滨州256603

出　　处：《国际医药卫生导报》2023年第11期1481-1485,共5页International Medicine and Health Guidance News

基　　金：山东省自然科学基金(ZR2022MH175);山东省研究生教育创新计划项目(20038612);滨州医学院附属医院科研创新团队项目(202031);滨州医学院附属医院后备领军人才项目(JC2019-03)。

摘　　要：程序性死亡受体1(programmed cell death 1,PD-1)/程序性死亡配体1(programmed cell death-ligand 1,PD-L1)是重要的免疫检查点,在抑制抗肿瘤免疫反应中起作用,参与肿瘤细胞免疫逃逸机制。PD-1/PD-L1抑制剂通过阻断活化的T细胞上的PD-1与表达PD-L1的肿瘤细胞结合,在非小细胞肺癌、晚期黑色素瘤、甲状腺癌等多种肿瘤治疗中取得了良好的治疗效果。本文主要对PD-1抑制剂在甲状腺癌治疗中的研究进展进行综述。Programmed cell death-1(PD-1)/programmed cell death-ligand 1(PD-L1)are important immune checkpoints,which play pivotal roles in suppressing anti-cancer immunity and are involved in immune escape mechanism of tumor cells.PD-1/PD-L1 inhibitors have achieved remarkable therapeutic effects in non-small-cell lung cancer,advanced melanoma,thyroid carcinoma,and other tumors by blocking the binding of PD-1 on activated T-cells to PD-L1 expressed on tumor cells.This paper mainly reviews the progress in PD-1 inhibitors in the treatment of thyroid carcinoma.

关 键 词：甲状腺癌 免疫检查点抑制剂 程序性死亡受体1 分子靶向治疗 进展 

分 类 号：R736.1[医药卫生—肿瘤]